Sana Biotechnology, Inc. highlighted that Nature Biotechnology has published a paper titled "Young glial progenitor cells competitively replace aged and diseased human glia in the adult chimeric mouse brain." This paper showed that when healthy wild-type (WT), pluripotent stem cell-derived glial progenitor cells (hGPCs) - the cells that give rise to the glial support cells of the brain - were transplanted into adult mice that had been neonatally transplanted with mutant Huntingtin (mHTT)-expressing hGPCs, the healthy cells outcompeted and eliminated the diseased glia, ultimately repopulating the brain with the healthy transplanted cells. These data establish an additional proof-of-concept for the development of SC379, Sana's pluripotent stem cell- derived GPC product candidate, as a potential therapy to deliver healthy allogeneic GPCs to patients with certain central nervous system disorders.